Skip to main content

Table 6 Baseline biochemical parameters in adult patients

From: The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics

Parameter

rhPTH(1-84)

(n=125)

Conventional therapy

(n=571)

Analysis populationa

(N=696)

n

Value

n

Value

n

Value

Total serum calcium, mmol/L

 Mean ± SD

83

2.2±0.34

489

2.2±0.21

572

2.2±0.24

 Median (range)

 

2.2 (1.30–3.53)

 

2.2 (1.15–3.15)

 

2.2 (1.15–3.53)

Serum phosphateb, mmol/L

 Mean ± SD

53

1.3±0.27

280

1.4±0.26

333

1.4±0.26

 Median (range)

 

1.3 (0.8–1.9)

 

1.3 (0.7–2.1)

 

1.3 (0.7–2.1)

Serum creatinine, μmol/L

 Mean ± SD

69

86.9±55.93

452

84.1±30.80

521

84.5±35.11

 Median (range)

 

74.3 (38.9–479.1)

 

78.3 (26.5–284.6)

 

77.8 (26.5–479.1)

eGFR, mL/min/1.73 m2

 Mean ± SD

69

83.2±23.73

454

80.2±24.34

523

80.6±24.25

 Median (range)

 

84.9 (8.2–128.5)

 

81.1 (0.5–162.5)

 

81.4 (0.5–162.5)

  1. eGFR estimated glomerular filtration rate, rhPTH(1-84) recombinant human parathyroid hormone (1-84)
  2. aBaseline is defined as the assessment at enrollment (visit 1). The baseline measurement was the most recent value before the first dose in patients receiving treatment with rhPTH(1-84); pediatric patients (n=27), those who received rhPTH(1-34) (n=14), and those with outlier data for total serum calcium <0.88 mmol/L, >5.00 mmol/L (<3.5 mg/dL, >20.0 mg/dL); serum phosphate <0.32 mmol/L, >2.58 mmol/L (<1.0 mg/dL, >8.0 mg/dL); serum creatinine <17.68 μmol/L, >884.00 μmol/L (<0.2 mg/dL, >10.0 mg/dL); eGFR no lower limit/except negative values excluded, >200.0 mL/min/1.73 m2, were excluded from the analysis
  3. bInorganic phosphate was measured